Lava Therapeutics raises $83M in Sequence C spherical for bispecific antibodies


venture capital,money,business,Investor

An organization growing bispecific antibodies in oncology has acquired its newest funding increase from the enterprise capital arms of two giant drug corporations.

Utrecht, Netherlands-based Lava Therapeutics said Thursday that it had raised $83 million in a Sequence C financing, led by two new buyers – Novo Ventures and Sanofi Ventures – with participation from new buyers that included Redmile Group, Ysios Capital and BB Pureos Bioventures. Present buyers Versant, Gilde Healthcare and MRL Ventures Fund additionally took half within the financing. Novo and Sanofi are respectively the enterprise capital arms of Danish drugmaker Novo Nordisk and French drugmaker Sanofi.

“This financing gives significant capital to advance our bispecific gamma-delta T cell engager portfolio into a number of proof-of-concept medical trials anticipated to begin in 2021 for the remedy of stable tumors and hematological malignancies,” Lava CEO Stephen Hurly stated in a press release. “We imagine our focused strategy, leveraging the distinctive options of gamma9-delta2 T cells with modern bispecific antibodies, will ship novel T cell-based therapies providing benefits over as we speak’s oncology remedies.”

The corporate stated it plans to make use of the cash to advance its pipeline and drug-development platform, which it describes as utilizing the properties of gamma-delta T cells – the surveillance cells of the immune system – to create immunotherapies focused to tumors.

In a normal sense, bispecific antibodies are a category of immuno-oncology medicine that work by concentrating on an antigen on the floor of a most cancers cell after which concentrating on a protein on the floor of a T cell and thus guiding the T cell to kill the most cancers cell. For instance, Amgen’s authorised drug Blincyto (blinatumomab), used to deal with acute lymphoblastic leukemia, targets the antigen CD19, which is very expressed in malignant B cells in ALL, after which makes use of CD3 on the surfaces of T cells to direct the latter to kill the previous. Most bispecific antibodies work alongside comparable traces, reminiscent of others beneath growth by Amgen, Johnson & Johnson and different corporations.

Photograph: claudenakagawa, Getty Pictures


Please enter your comment!
Please enter your name here